Development of 90Y-DOTA-nimotuzumab Fab fragment for radioimmunotherapy

Martinez, Luis; Castillo, Abmel Xiques; Calzada, Victoria; Cruz, Marylaine Pérez-Malo; Montaña, René Leyva; Barrabí, Minely Zamora; González, Ignacio Hernández; Pérez, Mariela León; Valdivia, Alejandro Arbesú

doi:10.1007/s10967-014-3402-9

Cited by 4 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential of [ 89 Zr]IIIB6 was evaluated by comparing its biodistribution post-mortem with [ 89 Zr]h-R3 and [ 89 Zr]oxalate (negative control) (Figure 4). H-R3 is a well studied stable monoclonal antibody approved for human use in tumor imaging and cancer therapy [13].…”

Section: Post-mortem Biodistribution Of [ 89 Zr]iiib6 and [ 89 Zr]h-r3mentioning

confidence: 99%

“…Target-specific nuclear imaging includes the use of monoclonal antibodies to provide very stable and target-specific PET imaging agents, making them epitope-specific carriers of radionuclides to the site of interest [12]. For instance, CIMAher® (Nimotuzumab, h-R3) is a well studied stable monoclonal antibody approved for human use in tumor imaging and cancer by targeting EGFR (epidermal growth factor receptor) binding [13]. Once radiolabeled, the antibody affords the opportunity to be a selective diagnostic radiotracer and is particularly useful in ovarian cancer diagnosis due to the overexpression of EGFR.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Molecular Imaging of a Zirconium-89 Labeled Antibody Targeting Plasmodium falciparum–Infected Human Erythrocytes

et al. 2019

Self Cite

View full text Add to dashboard Cite

Purpose: Nuclear imaging is an important pre-clinical research tool to study infectious diseases in vivo, and could be extended to investigate complex aspects of malaria infections.As such, we report for the first time successful radiolabeling of a novel antibody specific to Plasmodium-infected erythrocytes (IIIB6), it's in vitro assessment and molecular imaging in nude mice.Procedures: In vitro confocal microscopy was used to determine the stage-specificity of Plasmodium-infected erythrocytes recognised by IIIB6. To enable micro-PET/CT imaging, IIIB6 was conjugated to Bz-DFO-NCS and subsequently radiolabeled with zirconium-89.Healthy nude mice were injected with [ 89 Zr]IIIB6 and pharmacokinetics and organ uptake were monitored over 24 hours. This was followed by post mortem animal dissection to determine the biodistribution of [ 89 Zr]IIIB6.Results: IIIB6 recognised all the relevant stages of Plasmodium falciparum-infected erythrocytes (trophozoites, schizonts and gametocytes) that are responsible for severe malaria pathology. [ 89 Zr]IIIB6-radiolabeling yields were efficient at 84%-89%. Blood pool imaging analysis indicated a pharmacological half-life of 9.6 ± 2.5 h for [ 89 Zr]IIIB6. The highest standard uptake values were determined at 2-6 h in the liver followed by the spleen, kidneys, heart, stomach, lung, respectively. Minimal activity was present in muscle-and bone tissue. Conclusion:In vitro characterisation of IIIB6 and pharmacokinetic characterization of [ 89 Zr]IIIB6 revealed that this antibody has potential for future use in Plasmodium-infected mouse models to study malaria in a preclinical in vivo setting with PET/CT imaging.

show abstract

Section: Post-mortem Biodistribution Of [ 89 Zr]iiib6 and [ 89 Zr]h-r3mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%